cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oncocyte Corp
2 own
14 watching
Current Price
$0
$-0.01
(-3.1%)
logo-ocx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
47.06M
52-Week High
52-Week High
1.82
52-Week Low
52-Week Low
0.2418
Average Volume
Average Volume
0.19M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization47.06M
icon52-Week High1.82
icon52-Week Low0.2418
iconAverage Volume0.19M
iconDividend Yield--
iconP/E Ratio--
What does the Oncocyte Corp do?
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More
How much money does Oncocyte Corp make?
News & Events about Oncocyte Corp.
Globe Newswire
1month ago
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation(Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocytes workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has ...
Zolmax
1month ago
OncoCyte (NASDAQ:OCX Get Rating) and Lucira Health (NASDAQ:LHDX Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, ...
Zolmax
2 months ago
OncoCyte (NASDAQ:OCX Get Rating) had its price target cut by Benchmark to $3.00 in a research report sent to investors on Thursday, Stock Target Advisor reports. A number of other equities analysts have also weighed in on OCX. Needham & Company LLC lowered their target price on OncoCyte from $2.10 ...
Ticker Report
2 months ago
Piper Sandler lowered shares of OncoCyte (NASDAQ:OCX Get Rating) from an overweight rating to a neutral rating in a research note released on Thursday morning, The Fly reports. The brokerage currently has $0.50 target price on the stock, down from their previous target price of $1.00. OCX ...
Ticker Report
2 months ago
OncoCyte (NASDAQ:OCX Get Rating) had its price objective trimmed by Benchmark to $3.00 in a report released on Thursday morning, Stock Target Advisor reports. Several other research firms have also recently issued reports on OCX. Piper Sandler cut shares of OncoCyte from an overweight rating...
Frequently Asked Questions
Frequently Asked Questions
What is Oncocyte Corp share price today?
plus_minus_icon
Can Indians buy Oncocyte Corp shares?
plus_minus_icon
How can I buy Oncocyte Corp shares from India?
plus_minus_icon
Can Fractional shares of Oncocyte Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Oncocyte Corp stocks?
plus_minus_icon
What is today’s traded volume of Oncocyte Corp?
plus_minus_icon
What is today’s market capitalisation of Oncocyte Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Oncocyte Corp?
plus_minus_icon
What percentage is Oncocyte Corp down from its 52-Week High?
plus_minus_icon
What percentage is Oncocyte Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.01
(-3.1%)
logo-ocx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VBI Vaccines Inc
VBI Vaccines Inc
$0.57
$0.01 (1.66 %)
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.97
$0.00 (0.00 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.13
$0.06 (2.66 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.59
$0.00 (-0.23 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
VBI Vaccines Inc
VBI Vaccines Inc
$0.57
$0.01 (1.66 %)
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.97
$0.00 (0.00 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.13
$0.06 (2.66 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.59
$0.00 (-0.23 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00